论文部分内容阅读
目的观察培菲康及乳果糖口服液对亚临床肝性脑病患者数字连接试验及血氨、肝功能的治疗效果。方法 60例患者分为治疗组及对照组,对照组采取基础治疗,包括合理饮食,服用复合维生素B,益肝灵等。治疗组在对照组治疗的基础上应用培菲康胶囊及乳果糖口服液,二者分别于4周后观察数字连接试验及血氨、肝功能。结果 4周后治疗组及对照组差异有统计学意义(P<0.05),但肝功能改善方面未见差异。结论培菲康联合乳果糖口服液能改善亚临床肝性脑病患者的临床试验指标,对于预防其发展为肝性脑病有重要意义。
Objective To observe the therapeutic effect of pefiikang and lactulose oral liquid on digital connection test and blood ammonia and liver function in patients with subclinical hepatic encephalopathy. Methods Sixty patients were divided into treatment group and control group. The control group received basic treatment, including reasonable diet, taking vitamin B complex, Yiganling and so on. The treatment group was given Peifeikang capsule and lactulose oral solution on the basis of the control group, and the two groups were observed digital connection test and blood ammonia and liver function after 4 weeks respectively. Results After 4 weeks, the difference between the treatment group and the control group was statistically significant (P <0.05), but no difference was found in the improvement of liver function. Conclusions Pefloxacin combined with lactulose oral liquid can improve the clinical trial indexes of patients with subclinical hepatic encephalopathy, which is of great significance in preventing the development of hepatic encephalopathy.